Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.
Optical probes that make cancer cells glow and improve surgical tumor removal are in phase I and II clinical trials in humans. The probes could be commonplace in the next 5 to 10 years, hypothesize the researchers.
A new clinical trial aims to apply advanced image analysis techniques to 4D CT scans. Already a standard step in targeting lung cancer radiotherapy, the trial seeks to use the scans map areas of lung function without additional testing.
Researchers identified characteristics that may lead to low patient accrual for a clinical trial.
Excluding patients with renal insufficiency but good performance status from clinical trials due to concern of excessive hematologic toxicity or poor outcomes may not be necessary with appropriate dosing modifications.
Mandatory tumor tissue specimens and associated analyses for clinical trial participation appear to be a significant barrier to clinical trial enrollment and may delay treatment.
A recent study examined the efficacy of pembrolizumab for the treatment of previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Extra biopsies performed solely to study the pharmacodynamics of a new anticancer drug have no impact on subsequent drug development or on how physicians use these new drugs to treat future patients.
Patient education on clinical trials prior to the first oncologic visit improves knowledge, attitudes, and preparation for decision making about clinical trials.
The number of registered NIH-funded trials listed on ClinicalTrials.gov decreased between 2006 through 2014; however, the number of industry-funded trials increased substantially.
A joint effort from the EORTC, the EANM, the ESR, and the US NCI has resulted in establishing a foundation to improve the implementation and use of imaging biomarkers in cancer clinical trials.
In the first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA), a strong anti-myeloma response was observed.
A novel immunotherapeutic approach improved outcomes for patients with advanced bladder cancer, according to a recent study.
Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)November 25, 2015
More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.
Researchers announced a breakthrough advance in a world-first international clinical trial of a new drug to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma that is refractory or resistant to current chemotherapies.
The search for evidence to support the growing use of proton therapy for more cancers continues to uncover valuable findings. New data from clinical trials demonstrate the potential advantages of proton therapy over conventional radiation for pancreatic cancer, late-stage non-small cell lung cancer, chordoma, and chondrosarcoma.
Scientists have developed a blood test that could help pair cancer patients with the most suitable therapy for their disease, then track disease progression to see if the treatment is effective.
Patients with newly diagnosed cancer were less likely to participate in clinical trials if their annual household income was less than $50,000.
Cancer trial participation decreases with decreasing annual household income, according to recent data.
Atezolizumab may substantially change treatment strategies for patients with refractory lung cancer, according the first efficacy results from the POPLAR and BIRCH studies, which studied the PD-L1 antibody across treatment lines.
An international team of cancer researchers announced game-changing results in the treatment of certain lung cancers with nivolumab compared with chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy.
ONA presents an exclusive report on the initial findings on the safety profile of ibrutinib in asymptomatic patients with CLL, as presented at the International Workshop on Chronic Lymphocytic Leukemia.
Brentuximab vedotin is proven an effective and safe first course of treatment for older patients with Hodgkin lymphoma who are not candidates for chemotherapy.
A recent study showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients who ultimately take the drugs, raising questions about the direct applicability of trial data.
Scientists used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial.
Clinical Trial Demonstrates Safety of Immunotherapy Drug Combinations in Small Cell and Non-Small Cell Lung CancersSeptember 28, 2015
Pembrolizumab, an immunotherapy drug that unmasks cancer cells allowing the body's immune system to destroy tumors, appears to be safe in treating lung cancers, according to a study presented at the 16th World Conference on Lung Cancer.
Eight of 14 patients in the first clinical trial of personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing beyond 4.5 years.
Results are in from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.
A new technique has been developed by statisticians to help doctors optimize dosing new cancer treatments in phase I/II clinical trials.
A genetically engineered herpes virus can be used to kill off skin cancer cells and galvanize the immune system, according to phase 3 clinical trial data.
- Understanding Drug Naming Nomenclature
- Prostate-Specific Antigen (PSA) Test (Fact Sheet)
- CDK4/6 Inhibitors Exploit a Unique Vulnerability in Pancreatic Cancer
- Proposed Regimen for Ovarian Cancer Is Aggressive, But Could Achieve a 50% Cure Rate
- Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed
- Low-income Breast Cancer Survivors Benefit From Personalized Survivorship Care Plans
- Understanding Drug Naming Nomenclature
- Nurse Navigators Key to Seamless Transition From Pediatric to Adult Survivorship Care
- Common Painkiller Has Anticancer Effects
- Palliative Care is Cost Effective for Cancer Patients, and Increases With Comorbidities
- Understanding Participation Factors Related to Web- and Phone-based Tobacco Cessation Programs
- Satisfaction With Navigators Associated With Satisfaction With Cancer-related Care
- Earlier and More Frequent Tanning Bed Use by Women Associated With Melanoma Incidence and Age at Diagnosis
- Novel Procedures Improves Staging of Lymph Nodes in Patients With Breast Cancer
- Risk of Metabolic Syndrome Increased in Survivors of Childhood Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|